NAT2 and breast cancer: Among NAT2 fast acetylators, subjects with a history of more than 20 pack-years were nearly two times as likely (OR: 1.93, 95%CI: 1.01–3.69) to develop breast cancer as compared to individuals with a history of less than 20 pack-years; however, no association was detected among NAT2 slow acetylators.